Navigation Links
Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
Date:8/19/2007

HAYWARD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that Pfizer Inc. has initiated a Phase 1 clinical trial of motilin receptor agonist PF-04548043, formerly KOS-2187, a selective and potent motilin receptor agonist being developed for the treatment of gastroesophageal reflux disease (GERD) and potentially other gastrointestinal (GI) disorders. The Phase 1 clinical trial is designed to test the safety, tolerability and pharmacokinetics of PF-04548043 in healthy subjects. In December 2006, Kosan and Pfizer established a worldwide license agreement for Kosan's motilin agonist program, including KOS-2187 and related compounds, in a transaction potentially valued at $250 million for the successful development and commercialization of PF-04548043 for one indication as well as royalties on worldwide sales.

"Kosan today has four advancing clinical programs, underscoring the increasing value of our development pipeline," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "Consistent with Kosan's focus on oncology, we successfully out-licensed KOS-2187 and our motilin receptor agonist program to Pfizer, a company with a strong gastrointestinal capability that could best exploit its therapeutic and commercial potential. We appreciate Pfizer's commitment to the development and potential commercialization of this promising prokinetic compound and look forward to its rapid advancement through the clinic."

About PF-04548043 and Motilin Receptor Agonists

Motilin, a hormone secreted by the small intestine, stimulates gastrointestinal motility (movement). The activity of motilin is mediated through the G-protein coupled
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
5. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
6. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
7. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
11. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015   BioClinica®, Inc ., a specialty ... that it has acquired a leading global patient ... (Medici).  The acquisition includes affiliates MediciGlobal , ... provides a lost-to-follow-up patient locate service ( L2FU®) ... Medici, BioClinica will offer pharmaceutical companies ...
(Date:7/6/2015)... 6, 2015 Hologic, Inc. (NASDAQ: HOLX ... its financial results for the third quarter of fiscal ... closes.  In conjunction with the release, management will host ... Time. Interested participants may listen to the ... States ) or 719-325-4804 (for international callers) and ...
(Date:7/6/2015)... FARMINGTON, Conn. , July 6, ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... Series E warrants to purchase 21,917,808 shares of ... purchase 2,191,781 shares of its common stock.  Certain ...
Breaking Medicine Technology:BioClinica Acquires MediciGroup 2BioClinica Acquires MediciGroup 3Hologic to Announce Financial Results for the Third Quarter of Fiscal 2015 on Wednesday, July 29, 2015 2Palatin Technologies Completes $30 Million Financing 2Palatin Technologies Completes $30 Million Financing 3Palatin Technologies Completes $30 Million Financing 4Palatin Technologies Completes $30 Million Financing 5
... with high-dose clopidogrel on board?, CHICAGO, ... will shed,light on the ideal combination of ... shortly after percutaneous coronary intervention (PCI).,Specifically, study ... inhibitor of the clotting protein thrombin, is ...
... ... Study, PALM BEACH, Fla., March 28 NeoVista, Inc. ... feasibility,study of the company,s novel epiretinal brachytherapy for the wet ... Society,Meeting in Palm Beach, Florida. The promising data from the ...
Cached Medicine Technology:ISAR-REACT 3 Pits Bivalirudin vs. Unfractionated Heparin in PCI 2ISAR-REACT 3 Pits Bivalirudin vs. Unfractionated Heparin in PCI 3NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society 2NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society 3
(Date:7/6/2015)... FL (PRWEB) , ... July 06, 2015 , ... ... key areas of orthopaedic sports medicine, the American Orthopaedic Society for Sports Medicine ... Annual Meeting, July 9-12 in Orlando, FL. As a leader in orthopaedic ...
(Date:7/6/2015)... , ... July 06, 2015 , ... Shortly after opening ... , the leading network of doctors working on a lien basis. Dr. Lim ... Liens. , The daughter of two Cambodian refugees, Dr. Lim suffered with back pain ...
(Date:7/6/2015)... ... July 06, 2015 , ... Invitation to ... yet there is a large gap between the unmet health priorities in the ... health outcomes and reduce unnecessary or ineffective treatments or procedures. , This milestone ...
(Date:7/6/2015)... ... July 06, 2015 , ... The Asian-Pacific market for rheumatoid arthritis therapeutics ... to grow at a CAGR of over 3.2 percent in the years to come ... to be mainly spurred by an anticipated launch of a number of promising pipeline ...
(Date:7/6/2015)... ... 06, 2015 , ... Understanding the new ICD-10 requirements is ... the transition. ADVOCATE, the only 100% radiology, revenue cycle management company in the ... The ten tips are timely and relevant guidelines to help radiology practices avoid ...
Breaking Medicine News(10 mins):Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 2Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 3Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 4Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 5Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 6Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2
... to declare the production cost of new medicines, including ... Thai market, Siriwat Thiptaradol, secretary-general of Thailand's Food and ... ,According to Siriwat, the requirement to disclose ... bill being considered by the Office of the Council ...
... could survive. And they have, one in thirty. Such are ... // ,Most of these babies with disabilities ... all lived for no more than a few hours, according ... and Gynaecology study. ,About 190,000 abortions take place ...
... saga of the HPV vaccine seems to be following ... story of the Hepatitis B vaccine, //the subject of ... the merits of its inclusion in the mandatory immunization ... 250,000 Americans are down with Hepatitis B infection each ...
... seem to confirm that oatmeal is good for the heart. ... direct effect of eating oatmeal on reducing heart disease risk ... did produce an overall cholesterol-lowering effect. ,People ... products experienced a decrease in both total cholesterol and unhealthy ...
... percent surge in its profit at Rs.2 billion with a ... ,The firm's expenditure on research and development, during ... said in a statement. It also announced increase in dividend ... recommended by the court. ,"Our strategy of ...
... Health & Family Welfare, Smt. Panabaka Lakshmi Inaugurated the ... State Medicinal Plant// Boards on “Strategies for Conservation and ... ,The minister said that our strategies and action ... existing medicinal plants bio-diversity in the forest areas but ...
Cached Medicine News:Health News:Thailand Directs Pharma Companies to Declare Production Cost of Drugs 2Health News:Aborted Babies Survive, a British Study Says 2Health News:Wholegrain Oats may Help Lower Cholesterol 2Health News:Exports Of Herbal & Dietary Products Has Huge Potential 2
... ring electrodes feature a molded grip ... slider that moves smoothly and locks ... also feature ultraflexible, red-and-black, 61-cm (24-in) ... resistance of bend-relief protection at both ...
... bars made of silver/silver chloride have contacts ... easy separation into two individual tabs. For ... 17). Bar dimensions: 4 cm (1.6 in) ... 200-count package contains 50 individually sealed sets ...
... Video Camera System (NTSC)With Maxenon PowerPlus ... surgeon's eye view of any procedure. ... or digital files for later use. ... 8" to 36". Automatic Iris and ...
... and your patient warm, with the ... system.,Designed around the Coanda Effect, thousands ... air flow around your torso's blush ... the heat and stress induced environment ...
Medicine Products: